TNF-α acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle

被引:478
作者
Li, YP [1 ]
Chen, YL
John, J
Moylan, J
Jin, BW
Mann, DL
Reid, MB
机构
[1] Baylor Coll Med, Dept Med, Houston, TX 77030 USA
[2] Univ Kentucky, Coll Med, Dept Physiol, Med Ctr, Lexington, KY 40502 USA
关键词
tumor necrosis factor; muscle wasting; ubituitin conjugating activity;
D O I
10.1096/fj.04-2364com
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Atrogin1/MAFbx is an ubiquitin ligase that mediates muscle atrophy in a variety of catabolic states. We recently found that H2O2 stimulates atrogin1/MAFbx gene expression. Since the cytokine tumor necrosis factor-alpha (TNF-alpha) stimulates both reactive oxygen production and general activity of the ubiquitin conjugating pathway, we hypothesized that TNF-alpha would also increase atrogin1/MAFbx gene expression. As with H2O2, we found that TNF-alpha exposure upregulates atrogin1/MAF-bx mRNA within 2 h in C2C12 myotubes. Intraperitoneal injection of TNF-alpha increased atrogin1/MAFbx mRNA in skeletal muscle of adult mice within 4 h. Exposing myotubes to either TNF-alpha or H2O2 also produced general activation of the mitogen-activated protein kinases (MAPKs): p38, ERK1/2, and JNK. The increase in atrogin1/MAFbx gene expression induced by TNF-alpha was not altered significantly by ERK inhibitor PD98059 or the JNK inhibitor SP600125. In contrast, atrogin1/MAFbx up-regulation and the associated increase in ubiquitin conjugating activity were both blunted by p38 inhibitors, either SB203580 or curcumin. These data suggest that TNF-alpha acts via p38 to increase atrogin1/MAFbx gene expression in skeletal muscle.
引用
收藏
页码:362 / 370
页数:9
相关论文
共 46 条
[1]   SEPSIS-INDUCED MYOFIBRILLAR PROTEIN CATABOLISM IN RAT SKELETAL-MUSCLE [J].
AHMAD, S ;
KARLSTAD, MD ;
CHOUDHRY, MA ;
SAYEED, MM .
LIFE SCIENCES, 1994, 55 (18) :1383-1391
[2]   PD-098059 IS A SPECIFIC INHIBITOR OF THE ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE KINASE IN-VITRO AND IN-VIVO [J].
ALESSI, DR ;
CUENDA, A ;
COHEN, P ;
DUDLEY, DT ;
SALTIEL, AR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (46) :27489-27494
[3]   Insights into the pathogenesis of chronic heart failure: immune activation and cachexia [J].
Anker, SD ;
Rauchhaus, M .
CURRENT OPINION IN CARDIOLOGY, 1999, 14 (03) :211-216
[4]   SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase [J].
Bennett, BL ;
Sasaki, DT ;
Murray, BW ;
O'Leary, EC ;
Sakata, ST ;
Xu, WM ;
Leisten, JC ;
Motiwala, A ;
Pierce, S ;
Satoh, Y ;
Bhagwat, SS ;
Manning, AM ;
Anderson, DW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (24) :13681-13686
[5]   Identification of ubiquitin ligases required for skeletal muscle atrophy [J].
Bodine, SC ;
Latres, E ;
Baumhueter, S ;
Lai, VKM ;
Nunez, L ;
Clarke, BA ;
Poueymirou, WT ;
Panaro, FJ ;
Na, EQ ;
Dharmarajan, K ;
Pan, ZQ ;
Valenzuela, DM ;
DeChiara, TM ;
Stitt, TN ;
Yancopoulos, GD ;
Glass, DJ .
SCIENCE, 2001, 294 (5547) :1704-1708
[6]   Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants [J].
Buck, M ;
Chojkier, M .
EMBO JOURNAL, 1996, 15 (08) :1753-1765
[7]   Forkhead transcription factors: Key players in development and metabolism [J].
Carlsson, P ;
Mahlapuu, M .
DEVELOPMENTAL BIOLOGY, 2002, 250 (01) :1-23
[8]  
Carter Yvette, 2003, Surg Infect (Larchmt), V4, P17, DOI 10.1089/109629603764655245
[9]   CACHEXIA AND GRAFT-VS-HOST-DISEASE-TYPE SKIN CHANGES IN KERATIN PROMOTER-DRIVEN TNF-ALPHA TRANSGENIC MICE [J].
CHENG, J ;
TURKSEN, K ;
YU, QC ;
SCHREIBER, H ;
TENG, M ;
FUCHS, E .
GENES & DEVELOPMENT, 1992, 6 (08) :1444-1456
[10]   Temporal alterations in protein signaling cascades during recovery from muscle atrophy [J].
Childs, TE ;
Spangenburg, EE ;
Vyas, DR ;
Booth, FW .
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2003, 285 (02) :C391-C398